Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615985 | 0.89 | NOTUM (0.78) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL11711879 | 0.78 | NOTUM (0.64) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL17993966 | 0.78 | NOTUM (0.64) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL10738426 | 0.78 | NOTUM (1.00) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL11118984 | 0.78 | NOTUM (0.64) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL82595 | 0.78 | MAPT (0.69) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL11831417 | 0.78 | NOTUM (0.64) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL4582384 | 0.78 | NOTUM (0.64) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL1163779 | 0.78 | NOTUM (0.64) | MAPTNOTUMF2ALDH1A1KCNJ1 | |
| SCHEMBL8485436 | 0.78 | KCNJ1 (0.66) | MAPTNOTUMF2ALDH1A1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103657338-B | Process for absorbing acid compounds contained in gaseous effluents using an aqueous solution based on amines | IFP新能源公司 | 2017-08-25 | — | — | CN | claimed |
| JP-8134201-A | — | — | None | — | — | JP | disclosed |
| JP-8208826-A | — | — | None | — | — | JP | disclosed |
| US-20240358710-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | AF CHEMICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | AF CHEMICALS, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11591295-B2 | Affinity illudofulvene conjugates | AF CHEMICALS LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3440078-B1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2022-09-28 | — | — | EP | disclosed |
| CN-109415359-B | Heterocyclic GPR119 agonist compounds | 人类制药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220040191-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | AF CHEMICALS, LLC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3342765-B1 | CATHEPSIN K INHIBITOR AND APPLICATION THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| US-5843966-A | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| EP-0802912-A1 | PIPERIDINE DERIVATIVES HAVING TACHYKININ ANTAGONIST ACTIVITY | GLAXO GROUP LIMITED (GB) | 1997-10-29 | — | — | EP | disclosed |
| CN-1162596-A | Antiarrhythmic Agents | AMERICAN CYANAMID CO (US) | 1997-10-22 | — | — | CN | disclosed |
| JP-H08208826-A | PRODUCTION OF POLYCARBONATE | IDEMITSU KOSAN CO LTD | 1996-08-13 | — | — | JP | disclosed |
| WO-1996021661-A1 | PIPERIDINE DERIVATIVES HAVING TACHYKININ ANTAGONIST ACTIVITY | GLAXO GROUP LIMITED (GB) | 1996-07-18 | — | — | WO | disclosed |
| EP-0720609-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| JP-H08134201-A | POLYCARBONATE RESIN | IDEMITSU KOSAN CO LTD | 1996-05-28 | — | — | JP | disclosed |
| WO-1995008549-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040191-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | MYC, MYCBP, TP53 | MAPT 3248/4885NOTUM 4632/4885F2 1600/4885 |
| US-20240358710-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | MYC, MYCBP, TP53 | MAPT 3248/4885NOTUM 4632/4885F2 1600/4885 |
| US-11591295-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | MAPT 2405/4885NOTUM 2739/4885F2 745/4885 |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | MYC, MYCBP, TP53 | MAPT 3248/4885NOTUM 4632/4885F2 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.